title: Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
abstract: OBJECTIVE
  To compare the effects of long-term lansoprazole and omeprazole treatment (6 months) on serum gastrin levels.
  
  
  METHODS
  Forty duodenal ulcer patients without previous treatment with proton pump inhibitors were randomized to receive either 20 mg/day or omeprazole or 30 mg/day of lansoprazole. Serum gastrin levels were determined on entry and every 2 months. On finalizing the study antral and fundic biopsies were obtained for immunohistochemical analysis of the enterochromaffin-like cell population.
  
  
  RESULTS
  Before starting the treatment fasting serum gastrin was similar in both groups (108.7 +/- 60.9 pg/mL omeprazole; 102.7 +/- 56.9 pg/mL lansoprazole). The treatment with either omeprazole or lansoprazole increased serum gastrin levels, but the increase was mild, maximal at 2 months and similar between omeprazole and lansoprazole (113.44 +/- 114.9 pg/mL omeprazole vs 166.1 +/- 117.9 pg/mL lansoprazole; p > 0.05). When serum gastrin levels were individually analyzed by patient, most were below 200 pg/mL and only 3 patients (1 omeprazole/2 lansoprazole) had levels near 500 pg/mL which were not correlated with enterochromaffin-like cell hyperplasia.
  
  
  CONCLUSIONS
  Long-term treatment with either omeprazole or lansoprazole is safe, at least during 6 months, and results in mild hypergastrinemia. No differences between these two drugs were observed.
authors.affiliation: Clinic University Hospital, Zaragoza, Spain.
authors.forename: M T
authors.initials: MT
authors.lastname: Arroyo Villarino
authors.forename: A
authors.initials: A
authors.lastname: Lanas Arbeloa
authors.forename: F
authors.initials: F
authors.lastname: Esteva Díaz
authors.forename: J
authors.initials: J
authors.lastname: Ortego Fernández de Retana
authors.forename: R
authors.initials: R
authors.lastname: Sainz Samitier
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology*; D005755:Gastrins / Q000097:blood*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy / Q000473:pathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D005755:Gastrins; D064747:Lansoprazole; D009853:Omeprazole